Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Targeting NAD⁺ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

Mol Cancer Ther (2025) 24 (2): 200–213.

https://doi.org/10.1158/1535-7163.MCT-24-0225

Published: 04 February 2025

View article titled, Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

Includes: Supplementary data

Journal Articles

Abstract B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies

Nebojsa Skorupan, Cody J. Peer, Eve Koehler, Seth Steinberg, Jane B Trepel, William D Figg, Zhi-Ren Liu, Christine Alewine

Mol Cancer Ther (2023) 22 (12_Supplement): B047.

https://doi.org/10.1158/1535-7163.TARG-23-B047

Published: 01 December 2023

View article titled, Abstract B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies

Journal Articles

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS^Q61X Mutant Rhabdomyosarcoma

Natalia Garcia, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman, Cody J. Peer, William D. Figg, Myron S. Ignatius, Kris C. Wood, Peter J. Houghton, Angelina V. Vaseva

Mol Cancer Ther (2022) 21 (1): 170–183.

https://doi.org/10.1158/1535-7163.MCT-21-0194

Published: 07 January 2022

View article titled, Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Includes: Supplementary data

Journal Articles

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Keith T. Schmidt, Cindy H. Chau, Jonathan D. Strope, Alwin D.R. Huitema, Tristan M. Sissung, Douglas K. Price, William D. Figg

Mol Cancer Ther (2021) 20 (5): 915–924.

https://doi.org/10.1158/1535-7163.MCT-20-0228

Published: 01 May 2021

View article titled, Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Includes: Supplementary data

Journal Articles

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Bih-Rong Wei, Shelley B. Hoover, Cody J. Peer, Jennifer E. Dwyer, Hibret A. Adissu, Priya Shankarappa, Howard Yang, Maxwell Lee, Tyler J. Peat, William D. Figg, R. Mark Simpson

Mol Cancer Ther (2020) 19 (11): 2308–2318.

https://doi.org/10.1158/1535-7163.MCT-19-0858

Published: 03 November 2020

View article titled, Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Includes: Supplementary data

Journal Articles

Abstract A069: Mechanisms governing the transcriptional regulation of the liver-specific transporter OATP1B3 in prostate cancer

Roberto H Barbier, Edel M McCrea, Jonathan D Strope, Phoebe A Huang, Tristan M Sissung, Douglas K Price, Cindy H Chau, William D Figg

Mol Cancer Ther (2019) 18 (12_Supplement): A069.

https://doi.org/10.1158/1535-7163.TARG-19-A069

Published: 01 December 2019

View article titled, Abstract A069: Mechanisms governing the transcriptional regulation of the liver-specific transporter OATP1B3 in prostate cancer

Journal Articles

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Christine Alewine, Mehwish Iqra Ahmad, Cody J Peer, Seth Steinberg, William D Figg, Raffit Hassan, Ira Pastan

Mol Cancer Ther (2019) 18 (12_Supplement): A081.

https://doi.org/10.1158/1535-7163.TARG-19-A081

Published: 01 December 2019

View article titled, Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Journal Articles

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Laetitia Marzi, Keli Agama, Junko Murai, Simone Difilippantonio, Amy James, Cody J. Peer, William D. Figg, Daniel Beck, Mohamed S.A. Elsayed, Mark Cushman, Yves Pommier

Mol Cancer Ther (2018) 17 (8): 1694–1704.

https://doi.org/10.1158/1535-7163.MCT-18-0028

Published: 31 July 2018

View article titled, Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Includes: Supplementary data

Journal Articles

Abstract B43: ANG1005, a novel brain-penetrant drug conjugate, in CNS metastases from breast cancer: FLT-PET imaging as a predictor of response

Ciara C. O'Sullivan, Maria Lindenberg, Christine Bryla, Nicole Davarpanah, Cody Peer, Nicholas Patronas, Laleh Amiri-Kordestani, Sanjeeve Balasubramaniam, Tito Fojo, William D. Figg, Peter Choyke

Mol Cancer Ther (2015) 14 (12_Supplement_2): B43.

https://doi.org/10.1158/1535-7163.TARG-15-B43

Published: 01 December 2015

View article titled, Abstract B43: ANG1005, a novel brain-penetrant drug conjugate, in CNS metastases from breast cancer: FLT-PET imaging as a predictor of response

Journal Articles

Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues

Shaunna L. Beedie, Cody J. Peer, Steven Pisle, Erin R. Gardner, Chris Mahony, Shelby Barnett, Agnieszka Ambrozak, Michael Gütschow, Cindy H. Chau, Neil Vargesson, William D. Figg

Mol Cancer Ther (2015) 14 (10): 2228–2237.

https://doi.org/10.1158/1535-7163.MCT-15-0320

Published: 05 October 2015

View article titled, Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues

Journal Articles

Abstract B28: Organic anion transporting polypeptide 1B3 as a novel biomarker for hypoxia in prostate cancer.

Heather M. Pressler, Stephen Pisle, Tristan M. Sissung, Cheryl D. Cropp, Douglas K. Price, William D. Figg

Mol Cancer Ther (2011) 10 (11_Supplement): B28.

https://doi.org/10.1158/1535-7163.TARG-11-B28

Published: 12 November 2011

View article titled, Abstract B28: Organic anion transporting polypeptide 1B3 as a novel biomarker for hypoxia in prostate cancer.

Journal Articles

Abstract A110: A phase 1 study of PF‐04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with refractory solid tumor malignancies and lymphoma

Giuseppe Giaccone, Arun Rajan, Sonja Crandon, Martin Gutierrez, Shivaani Kummar, Lokesh Jain, William D. Figg, Brett E. Houk, Michael Shnaidman, Jamey Skillings

Mol Cancer Ther (2009) 8 (12_Supplement): A110.

https://doi.org/10.1158/1535-7163.TARG-09-A110

Published: 10 December 2009

View article titled, Abstract A110: A phase 1 study of PF‐04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with refractory solid tumor malignancies and lymphoma

Journal Articles

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

Lokesh Jain, Craig A. Vargo, Romano Danesi, Tristan M. Sissung, Douglas K. Price, David Venzon, Jürgen Venitz, William D. Figg

Mol Cancer Ther (2009) 8 (9): 2496–2508.

https://doi.org/10.1158/1535-7163.MCT-09-0302

Published: 17 September 2009

View article titled, The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

Includes: Supplementary data

Journal Articles

Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1

Rui Gao, Douglas K. Price, Tristan Sissung, Eddie Reed, William D. Figg

Mol Cancer Ther (2008) 7 (5): 1246–1250.

https://doi.org/10.1158/1535-7163.MCT-07-2206

Published: 15 May 2008

View article titled, Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1

Journal Articles

Association of the CYP1B13* allele with survival in patients with prostate cancer receiving docetaxel

Tristan M. Sissung, Romano Danesi, Douglas K. Price, Seth M. Steinberg, Ronald de Wit, Muhammad Zahid, Nilesh Gaikwad, Ercole Cavalieri, William L. Dahut, Dan L. Sackett, William D. Figg, Alex Sparreboom

Mol Cancer Ther (2008) 7 (1): 19–26.

https://doi.org/10.1158/1535-7163.MCT-07-0557

Published: 17 January 2008

View article titled, Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

Journal Articles

Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay

Gordon R. Macpherson, Sylvia S.W. Ng, Siiri L. Forbes, Giovanni Melillo, Tatiana Karpova, James McNally, Thomas P. Conrads, Timothy D. Veenstra, Alfredo Martinez, Frank Cuttitta, Douglas K. Price, William D. Figg

Mol Cancer Ther (2003) 2 (9): 845–854.

Published: 10 October 2003

View article titled, Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay

NARROW

Targeting NAD⁺ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

Abstract B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS^Q61X Mutant Rhabdomyosarcoma

Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Abstract A069: Mechanisms governing the transcriptional regulation of the liver-specific transporter OATP1B3 in prostate cancer

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Abstract B43: ANG1005, a novel brain-penetrant drug conjugate, in CNS metastases from breast cancer: FLT-PET imaging as a predictor of response

Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues

Abstract B28: Organic anion transporting polypeptide 1B3 as a novel biomarker for hypoxia in prostate cancer.

Abstract A110: A phase 1 study of PF‐04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with refractory solid tumor malignancies and lymphoma

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1

Association of the CYP1B13* allele with survival in patients with prostate cancer receiving docetaxel

Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only